- Metronidazol: einfacher Verlauf
- Vancomycin und Metronidazol: schwerer Verlauf
- Schmalspektrum-Makrolid Fidaxomicin (Dificlir®) kann Vancomycin ersetzen.
- Antibiotika in Prüfung: Teicoplanin, Ramoplanin, Fusidic acid, Nitazoxanide, Rifampin, Bacitracin
- Toxin-Antikörper: Actoxumumab, Bezlotoxumumab(2)
- Clostridien-Sporen von Gesunden (in Erprobung)(6)
Clostridium Difficile Colitis:Review of the Therapeutic Approach.
Am J Ther. 2012 Sep 17. [Epub ahead of print]
2.) Wilcox MH, et al. for the MODIFY I and MODIFY II Investigators.
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
N Engl J Med 2017;376:305-17.
DOI: 10.1056/NEJMoa1602615
3.) Tariq R, et al.:
Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis.
JAMA Intern Med. 2017;
doi: 10.1001/jamainternmed.2017.0212.
4.) Weiss K, et al.:
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea.
BMJ Open Gastroenterol 2015; 2: e000028.
5.) Freedberg DE, et al.:
Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
Am J Gastroenterol. 2013;108: 1794–801.
6.) Studie NCT03183128:
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)
Teil von
